Adverse outcomes between VMAT2 and anticholinergics in tardive dyskinesia: A target trial emulation
Psychiatry and Clinical Neurosciences · 2026-08 · 80 (8) · 637-644
DOI: 10.1111/pcn.70056 ↗Kurz gefasst
Fachartikel in der Zeitschrift Psychiatry and Clinical Neurosciences, online erschienen am 07.04.2026. Verfasst von Tien-Wei Hsu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, E-DA Dachang Hospital, I-Shou University, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Vesicular Monoamine Transport Proteins, Cholinergic Antagonists, Tardive Dyskinesia, Accidental Falls. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Tri-Service General Hospital, Ministry of National Defense Medical Affairs Bureau, National Science and Technology Council.
Abstract (Originalsprache)
Aim
Vesicular monoamine transporter 2 (VMAT2) inhibitors have been approved for the treatment of tardive dyskinesia (TD), whereas anticholinergic agents are still widely used for this condition. This study aimed to compare the risk of major clinical adverse outcomes among patients with TD treated with VMAT2 inhibitors versus anticholinergic agents.
Methods
This retrospective cohort study used the TriNetX collaborative network, which aggregates de‐identified electronic health records (EHRs) across the United States. Adults aged≧18 years with TD who initiated anticholinergic agents or VMAT2 inhibitors for the first time between 2019 and 2025 were included. We applied a target trial emulation framework under the intention‐to‐treat principle. 1:1 propensity score matching was applied. Cox hazard regression was used to assess the primary outcomes: incident fall, injury, fracture, and mortality, and secondary outcomes: incident delirium, dementia, and arrythmia.
Results
After propensity score matching, 2749 patients (mean age: 59 years; 34% male) were included in each treatment group with well‐balanced demographics. Compared with anticholinergic therapy, VMAT2 inhibitors were associated with significantly lower risks of fall (HR = 0.83, 95% CI = 0.73–0.93), injury (HR = 0.77, 95% CI = 0.71–0.85), fracture (HR = 0.82, 95 % CI = 0.72–0.94), and mortality (HR = 0.71, 95% CI = 0.58–0.87). Secondary outcomes also favored VMAT2 inhibitors, with reduced risks of delirium (HR = 0.39, 95% CI = 0.29–0.52), dementia (HR = 0.55, 95 % CI = 0.45–0.69), and arrhythmia (HR = 0.72, 95% CI = 0.60–0.85).
Conclusion
This real‐world study suggests that VMAT2 inhibitors may offer a safer therapeutic option than anticholinergic agents for TD management, supporting their potential clinical advantage and the need for further long‐term validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, E-DA Dachang Hospital, I-Shou University, Kaohsiung, Taiwan.
- Department of Psychiatry, E-DA Hospital, I-Shou University, Kaohsiung, Taiwan.
- School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan.
- Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
- Institute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung, Taiwan.
- Department of Psychology, College of Medical and Health Science, Asia University, Taichung, Taiwan.
ORCID-Profile: Tien-Wei Hsu, Chih-Wei Hsu, Ping-Tao Tseng, Jen-Ping Chen, Fu-Chi Yang, Chia-Kuang Tsai, Chih-Sung Liang
Förderung
- Tri-Service General Hospital
- Ministry of National Defense Medical Affairs Bureau
- National Science and Technology Council
Zitieren
APA
Hsu, T. W., Hsu, C. W., Tseng, P. T., Fang, Y. Y., Lee, C. Y., Lin, Y. H., Stubbs, B., Thompson, T., Carvalho, A. F., Kao, Y. C., Chen, J. P., Yang, F. C., Tsai, C. K., & Liang, C. S. (2026). Adverse outcomes between VMAT2 and anticholinergics in tardive dyskinesia: A target trial emulation. Psychiatry and Clinical Neurosciences, 80(8), 637-644. https://doi.org/10.1111/pcn.70056
Vancouver
Hsu TW, Hsu CW, Tseng PT, Fang YY, Lee CY, Lin YH, et al. Adverse outcomes between VMAT2 and anticholinergics in tardive dyskinesia: A target trial emulation. Psychiatry and Clinical Neurosciences. 2026;80(8):637-644. doi:10.1111/pcn.70056
BibTeX
@article{Hsu2026,
author = {Hsu, Tien-Wei and Hsu, Chih-Wei and Tseng, Ping-Tao and Fang, Yi-Ya and Lee, Chuo-Yu and Lin, Yu-Hsuan and Stubbs, Brendon and Thompson, Trevor and Carvalho, Andre F and Kao, Yu-Chen and Chen, Jen-Ping and Yang, Fu-Chi and Tsai, Chia-Kuang and Liang, Chih-Sung},
title = {Adverse outcomes between VMAT2 and anticholinergics in tardive dyskinesia: A target trial emulation},
journal = {Psychiatry and Clinical Neurosciences},
year = {2026},
volume = {80},
number = {8},
pages = {637--644},
doi = {10.1111/pcn.70056}
}
EUVIMED